8-K filing — Fidelity Core Real Estate Fund
Filed: 2026-09-08 AccNo: 0001193125-26-384481 Size: 11 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Filed: 2026-09-08 AccNo: 0001193125-26-384481 Size: 11 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Senate’s Sep. 15 Clarity Act vote faces ethics and stablecoin disputes; failure could spur agency rules as crypto expands into traditional finance.
Filed: 2026-09-08 AccNo: 0001326380-26-000050 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-08 AccNo: 0001104659-26-105722 Size: 343 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Baidu (BIDU) slips 8% premarket to test $89.60 support. Get the latest analyst price targets and Stock Connect program updates.
Filed: 2026-09-08 AccNo: 0001493152-26-041716 Size: 265 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-08 AccNo: 0001104659-26-105719 Size: 187 KB Item 7.01: Regulation FD Disclosure
Filed: 2026-09-08 AccNo: 0001104659-26-105718 Size: 189 KB Item 3.02: Unregistered Sales of Equity Securities
Filed: 2026-09-08 AccNo: 0001193125-26-384471 Size: 171 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
https://www.bloomberg.com/news/articles/2026-09-08/europe-set-to-buy-patriots-from-us-to-shield-ukraine-this-winter
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001500435/000150043526000040/gpro-20260908.htm
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune